{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:57:36Z","timestamp":1793275056668,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073620"],"award-info":[{"award-number":["82073620"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018617","name":"Liaoning Revitalization Talents Program","doi-asserted-by":"publisher","award":["XLYCYSZX1904"],"award-info":[{"award-number":["XLYCYSZX1904"]}],"id":[{"id":"10.13039\/501100018617","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Evidence on the willingness of men who have sex with men (MSM) with oral pre-exposure prophylaxis (PrEP) experience, especially those with suboptimal adherence, to take long-acting injectable PrEP (LAI-PrEP) is critical to guide future LAI-PrEP implementation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The objective was to assess the willingness of MSM with oral PrEP experience to take LAI-PrEP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>MSM who participated in the China Real-world Study of Oral PrEP (CROPrEP) were enrolled in this study. Information on the willingness of MSM to take LAI-PrEP and potential correlates was collected using a structured online questionnaire. The main outcomes were the willingness of MSM to take LAI-PrEP and its association with HIV-related behaviours, sexually transmitted infections, and oral PrEP history. Logistic regression was used to identify correlates of the willingness of MSM to take LAI-PrEP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 612 former CROPrEP participants (FCPs) were included in this study. There were 315 (51.5%) daily oral PrEP (D-PrEP) users and 297 (48.5%) event-driven oral PrEP (ED-PrEP) users at the last follow-up. Most FCPs (77.8%) were willing to take free LAI-PrEP. FCPs with no less than two sexual male\u00a0partners (aOR\u2009=\u20091.54, [95% CI: 1.04, 2.29], <jats:italic>P<\/jats:italic>\u2009=\u20090.031), those with male partners with unknown HIV statuses (aOR\u2009=\u20092.04, [95% CI: 1.31, 3.18], <jats:italic>P<\/jats:italic>\u2009=\u20090.002), those with recreational drug use (aOR\u2009=\u20091.58, [95% CI: 1.05, 2.40], <jats:italic>P<\/jats:italic>\u2009=\u20090.030), and those with HSV-2 positivity\u00a0(aOR\u2009=\u20092.15, [95% CI: 1.30, 3.57], <jats:italic>P<\/jats:italic>\u2009=\u20090.003) were more willing to take LAI-PrEP, while ED-PrEP users (aOR\u2009=\u20090.66, [95% CI: 0.45, 0.98], <jats:italic>P<\/jats:italic>\u2009=\u20090.037) and FCPs with suboptimal oral PrEP adherence (aOR\u2009=\u20090.58, [95% CI: 0.36, 0.94], <jats:italic>P<\/jats:italic>\u2009=\u20090.026) were less willing to take LAI-PrEP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>LAI-PrEP has good prospects for expanding PrEP coverage. However, FCPs with suboptimal oral PrEP\u00a0adherence are less likely to take LAI-PrEP. Further intervention and implementation efforts are needed to improve the willingness of MSM to use LAI-PrEP, and sexual health should be considered during the discussion about PrEP initiation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-023-17325-9","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T11:02:05Z","timestamp":1702465325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Willingness to take long-acting injectable pre-exposure prophylaxis among men who have sex with men who participated in the CROPrEP study: a cross-sectional online study"],"prefix":"10.1186","volume":"23","author":[{"given":"Yingjie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoJie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YaoKai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehua","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YongJun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenQing","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baosen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"17325_CR1","unstructured":"WHO. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. Geneva: World Health Organization; 2015 Sep. Available from: [https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK327115\/]."},{"key":"17325_CR2","unstructured":"UNAIDS, UNAIDS data 2021. Available from: [https:\/\/www.unaids.org\/en\/resources\/documents\/2021\/2021_unaids_data]."},{"key":"17325_CR3","doi-asserted-by":"crossref","unstructured":"Huang X, Hou J, Song A, Liu X, Yang X, Xu J, et al. Efficacy and safety of oral TDF-based pre-exposure prophylaxis for men who have sex with men: a systematic review and meta-analysis. Front Pharmacol. 2018;9:799.","DOI":"10.3389\/fphar.2018.00799"},{"issue":"1","key":"17325_CR4","first-page":"1","volume":"26","author":"SP Buchbinder","year":"2018","unstructured":"Buchbinder SP, Liu AY. CROI 2018: Epidemic Trends and Advances in HIV Prevention. Top Antivir Med. 2018;26(1):1\u201316.","journal-title":"Top Antivir Med"},{"key":"17325_CR5","unstructured":"AIDS Vaccine Advocacy Coalition (AVAC). Global PrEP Use Landscape as of March 2022. Available from: [https:\/\/www.prepwatch.org\/resource\/global-prep-tracker\/]."},{"key":"17325_CR6","doi-asserted-by":"crossref","unstructured":"Wang H, Wang Z, Huang X, Chen Y, Wang H, Cui S, et al. Association of HIV Pre-exposure Prophylaxis use with HIV incidence among men who have sex with men in China: a nonrandomized controlled trial. JAMA Netw Open. 2022;5(2):e2148782.","DOI":"10.1001\/jamanetworkopen.2021.48782"},{"issue":"11","key":"17325_CR7","first-page":"1265","volume":"26","author":"J Xu","year":"2020","unstructured":"Xu J, Huang X, Liu X, Wang L, Chen K, Wang H, et al. Chinese HIV PrEP experts consensus. Chin J AIDS STD. 2020;26(11):1265\u201371.","journal-title":"Chin J AIDS STD"},{"key":"17325_CR8","unstructured":"[Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2021 edition)]. Zhonghua Nei Ke Za Zhi 2021, 60(12):1106\u20131128."},{"key":"17325_CR9","doi-asserted-by":"crossref","unstructured":"Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al.\u00a0Pre-exposure\u00a0chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399.","DOI":"10.1056\/NEJMoa1011205"},{"issue":"10","key":"17325_CR10","doi-asserted-by":"publisher","first-page":"e059034","DOI":"10.1136\/bmjopen-2021-059034","volume":"12","author":"H Zhang","year":"2022","unstructured":"Zhang H, Wang M, Zhang Y, Tan S, Huang H, Zhu J, et al. Usability of dual HIV\/syphilis self-testing among men who have sex with men in China: study protocol for a three-arm randomised controlled trial. BMJ Open. 2022;12(10):e059034.","journal-title":"BMJ Open"},{"issue":"5 Suppl 1","key":"17325_CR11","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.amepre.2021.04.036","volume":"61","author":"LE Garrison","year":"2021","unstructured":"Garrison LE, Haberer JE. Pre-exposure Prophylaxis Uptake, Adherence, and Persistence: A Narrative Review of Interventions in the U.S. Am J Prev Med. 2021;61(5 Suppl 1):S73\u2013s86.","journal-title":"Am J Prev Med"},{"issue":"5","key":"17325_CR12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1521\/aeap.2020.32.5.416","volume":"32","author":"SZ Ching","year":"2020","unstructured":"Ching SZ, Wong LP, Said MAB, Lim SH. Meta-synthesis of Qualitative Research of Pre-exposure Prophylaxis (PrEP) Adherence Among Men Who Have Sex With Men (MSM). AIDS Educ Prev. 2020;32(5):416\u201331.","journal-title":"AIDS Educ Prev"},{"issue":"4","key":"17325_CR13","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00030-3","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Li C, Xu J, Hu Z, Rutstein SE, Tucker JD, et al. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV. 2022;9(4):e254\u201368.","journal-title":"Lancet HIV"},{"issue":"9","key":"17325_CR14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/17425247.2020.1783233","volume":"17","author":"DA Cobb","year":"2020","unstructured":"Cobb DA, Smith NA, Edagwa BJ, McMillan JM. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. Expert Opin Drug Deliv. 2020;17(9):1227\u201338.","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"17325_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/COH.0000000000000734","volume":"17","author":"O Sued","year":"2022","unstructured":"Sued O, Nardi N, Spadaccini L. Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review. Curr Opin HIV AIDS. 2022;17(3):145\u201361.","journal-title":"Curr Opin HIV AIDS"},{"key":"17325_CR16","doi-asserted-by":"crossref","unstructured":"Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595\u2013608.","DOI":"10.1056\/NEJMoa2101016"},{"key":"17325_CR17","unstructured":"the U.S. Food and Drug Administration. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. December 20, 2021 [https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention]."},{"key":"17325_CR18","unstructured":"National Medical Products Administration. The drug approval document service information on July 13, 2023 [https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20230713154938169.html]."},{"issue":"7","key":"17325_CR19","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1007\/s10461-022-03575-y","volume":"26","author":"A Ogunbajo","year":"2022","unstructured":"Ogunbajo A, Tsai AC, Kanki PJ, Mayer KH. Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and Other PrEP Modalities among Sexual Minority Men in Nigeria. Africa AIDS Behav. 2022;26(7):2363\u201375.","journal-title":"Africa AIDS Behav"},{"issue":"1","key":"17325_CR20","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1186\/s12879-019-4692-x","volume":"19","author":"W Huang","year":"2019","unstructured":"Huang W, Wu D, Ong JJ, Smith MK, Pan S, Yang F, et al. Prepared for PrEP: preferences for HIV pre-exposure prophylaxis among Chinese men who have sex with men in an online national survey. BMC Infect Dis. 2019;19(1):1057.","journal-title":"BMC Infect Dis"},{"key":"17325_CR21","doi-asserted-by":"crossref","unstructured":"Meyers K, Wu Y, Qian H, Sandfort T, Huang X, Xu J, et al. Interest in long-acting injectable PrEP in a cohort of men who have sex with men in China. AIDS Behav. 2018;22(4):1217\u201327.","DOI":"10.1007\/s10461-017-1845-z"},{"key":"17325_CR22","doi-asserted-by":"crossref","unstructured":"Chan C, Vaccher S, Fraser D, Grulich AE, Holt M, Zablotska-Manos I, et al. Preferences for Current and Future PrEP Modalities Among PrEP-Experienced Gay and Bisexual Men in Australia. AIDS Behav. 2022;26(1):88\u201395.","DOI":"10.1007\/s10461-021-03344-3"},{"key":"17325_CR23","doi-asserted-by":"crossref","unstructured":"Levy ME, Agopian A, Magnus M, Rawls A, Opoku J, Kharfen M, et al. Is Long-acting injectable cabotegravir likely to expand PrEP coverage among MSM in the district of Columbia? J Acquir Immune Defic Syndr. 2021;86(3):e80\u20132.","DOI":"10.1097\/QAI.0000000000002557"},{"issue":"7","key":"17325_CR24","doi-asserted-by":"publisher","first-page":"e0200296","DOI":"10.1371\/journal.pone.0200296","volume":"13","author":"K Meyers","year":"2018","unstructured":"Meyers K, Wu Y, Brill A, Sandfort T, Golub SA. To switch or not to switch: Intentions to switch to injectable PrEP among gay and bisexual men with at least twelve months oral PrEP experience. PLoS One. 2018;13(7):e0200296.","journal-title":"PLoS One"},{"issue":"151","key":"17325_CR25","doi-asserted-by":"publisher","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","volume":"4","author":"PL Anderson","year":"2012","unstructured":"Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casap\u00eda M, Montoya-Herrera O, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125.","journal-title":"Sci Transl Med"},{"issue":"23","key":"17325_CR26","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"JM Molina","year":"2015","unstructured":"Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373(23):2237\u201346.","journal-title":"N Engl J Med"},{"issue":"4","key":"17325_CR27","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s10461-017-1907-2","volume":"22","author":"SA John","year":"2018","unstructured":"John SA, Whitfield THF, Rendina HJ, Parsons JT, Grov C. Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available? AIDS Behav. 2018;22(4):1184\u20139.","journal-title":"AIDS Behav"},{"issue":"3","key":"17325_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10900-023-01195-8","volume":"48","author":"K Paudel","year":"2023","unstructured":"Paudel K, Gupta S, Gautam K, Wickersham JA, Khati A, Azwa I, Ha T, Shrestha R. High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia. J Community Health. 2023;48(3):513\u201321.","journal-title":"J Community Health"},{"issue":"10","key":"17325_CR29","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1080\/17425247.2022.2135699","volume":"19","author":"V Agrahari","year":"2022","unstructured":"Agrahari V, Anderson SM, Peet MM, Wong AP, Singh ON, Doncel GF, et al. Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges. Expert Opin Drug Deliv. 2022;19(10):1365\u201380.","journal-title":"Expert Opin Drug Deliv"},{"key":"17325_CR30","doi-asserted-by":"crossref","unstructured":"Chen W, Ding Y, Chen J, Zhao P, Wang Z, Meng X, et al. Awareness of and preferences for pre-exposure prophylaxis (PrEP) among MSM at high risk of HIV infection in Southern China: findings from the T2T study. Biomed Res Int. 2021;2021:6682932.","DOI":"10.1155\/2021\/6682932"},{"issue":"7","key":"17325_CR31","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s10508-017-1083-5","volume":"47","author":"WC Goedel","year":"2018","unstructured":"Goedel WC, Schneider JA, Hambrick HR, Kreski NT, Morganstein JG, Park SH, Mgbako O, Duncan DT. Are Anal Sex Roles Associated with Preferences for Pre-Exposure Prophylaxis Administration Modalities Among Men Who Have Sex with Men? Arch Sex Behav. 2018;47(7):2123\u201333.","journal-title":"Arch Sex Behav"},{"issue":"9","key":"17325_CR32","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1007\/s10461-020-02808-2","volume":"24","author":"EE Tolley","year":"2020","unstructured":"Tolley EE, Zangeneh SZ, Chau G, Eron J, Grinsztejn B, Humphries H, Liu A, Siegel M, Bertha M, Panchia R, et al. Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077. AIDS Behav. 2020;24(9):2520\u201331.","journal-title":"AIDS Behav"},{"issue":"1","key":"17325_CR33","doi-asserted-by":"publisher","first-page":"e25664","DOI":"10.1002\/jia2.25664","volume":"24","author":"G Mansergh","year":"2021","unstructured":"Mansergh G, Kota KK, Stephenson R, Hirshfield S, Sullivan P. Preference for using a variety of future HIV pre-exposure prophylaxis products among men who have sex with men in three US cities. J Int AIDS Soc. 2021;24(1):e25664.","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"17325_CR34","doi-asserted-by":"publisher","first-page":"e114700","DOI":"10.1371\/journal.pone.0114700","volume":"9","author":"K Meyers","year":"2014","unstructured":"Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS ONE. 2014;9(12):e114700.","journal-title":"PLoS ONE"},{"issue":"8","key":"17325_CR35","doi-asserted-by":"publisher","first-page":"e0183521","DOI":"10.1371\/journal.pone.0183521","volume":"12","author":"ME Levy","year":"2017","unstructured":"Levy ME, Patrick R, Gamble J, Rawls A, Opoku J, Magnus M, Kharfen M, Greenberg AE, Kuo I. Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxis. PLoS One. 2017;12(8):e0183521.","journal-title":"PLoS One"},{"issue":"1","key":"17325_CR36","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1186\/s12889-022-14134-4","volume":"22","author":"L Pedrana","year":"2022","unstructured":"Pedrana L, Magno L, Zucchi EM, da Silva LAV, Ferraz D, Grangeiro A, Castellanos M, Brasil SA, Dourado I. Zero knowledge and high interest in the use of long-acting injectable pre-exposure prophylaxis (PrEP) among adolescent men who have sex with men and transgender women in two capital cities in Brazil. BMC Public Health. 2022;22(1):1728.","journal-title":"BMC Public Health"},{"key":"17325_CR37","doi-asserted-by":"publisher","unstructured":"Oldenburg CE, Le B, Huyen HT, Thien DD, Quan NH, Biello KB, et al. Antiretroviral pre-exposure prophylaxis preferences among men who have sex with men in Vietnam: results from a nationwide cross-sectional survey. Sex Health. 2016. https:\/\/doi.org\/10.1071\/SH15144.","DOI":"10.1071\/SH15144"},{"key":"17325_CR38","doi-asserted-by":"crossref","unstructured":"Greene GJ, Swann G, Fought AJ, Carballo-Di\u00e9guez A, Hope TJ, Kiser PF, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among U.S. men who have sex with men. AIDS Behav. 2017;21(5):1336\u201349.","DOI":"10.1007\/s10461-016-1565-9"},{"key":"17325_CR39","doi-asserted-by":"crossref","unstructured":"Ellison J, van den Berg JJ, Montgomery MC, Tao J, Pashankar R, Mimiaga MJ, et al. Next-generation HIV pre-exposure prophylaxis preferences among men who have sex with men taking daily oral pre-exposure prophylaxis. AIDS Patient Care STDS. 2019;33(11):482\u201391.","DOI":"10.1089\/apc.2019.0093"},{"issue":"10","key":"17325_CR40","first-page":"1363","volume":"38","author":"Y Liu","year":"2017","unstructured":"Liu Y, Tang HF, Ning Z, Zheng H, He N, Zhang YY. Co-infections of HIV, syphilis and HSV-2 among men who have sex with men at the voluntary HIV counseling and testing clinics in Shanghai. Zhonghua Liu Xing Bing Xue Za Zhi. 2017;38(10):1363\u20136.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"17325_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijmmb.2022.09.007","volume":"42","author":"HG Ouedraogo","year":"2023","unstructured":"Ouedraogo HG, Zida S, Sagna T, Zoure AA, Compaore RT, Soubeiga ST, et al. Herpes simplex virus type 2 (HSV-2) and its association with HIV, HCV, HBV, HTLV-1&2 and syphilis among men who have sex with men in Burkina Faso. Indian J Med Microbiol. 2023;42:59\u201364.","journal-title":"Indian J Med Microbiol."},{"key":"17325_CR42","doi-asserted-by":"crossref","unstructured":"Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, et al. Changes in kidney function associated with daily Tenofovir Disoproxil Fumarate\/Emtricitabine for HIV Preexposure Prophylaxis use in the United States demonstration project. J Acquir Immune Defic Syndr. 2017;77(2):193\u20138.","DOI":"10.1097\/QAI.0000000000001566"},{"issue":"8","key":"17325_CR43","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1016\/S2352-3018(22)00133-3","volume":"9","author":"JM Molina","year":"2022","unstructured":"Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, et al. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Lancet HIV. 2022;9(8):e554\u201362.","journal-title":"Lancet HIV"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-17325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-023-17325-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-17325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T11:02:34Z","timestamp":1702465354000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-023-17325-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["17325"],"URL":"https:\/\/doi.org\/10.1186\/s12889-023-17325-9","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board at the First Hospital of China Medical University ([2020]-327). Ethics approval and written consent was obtained from each participant before the collection of data. Written informed consent was obtained from all the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2494"}}